NFE2L2 and cancer: While position 19-substituted geldanamycins have been developed to ameliorate this toxicity by blocking the reaction of the compounds with biological nucleophiles [133], we would like to propose an alternative approach in which geldanamycins are used for the treatment of NRF2-addicted cancers based on the synthetic lethal mechanism.